Jani AB, Schreibmann E, Goyal S, et al. - Researchers conducted a single-centre, open-label, phase 2/3 randomised controlled trial (EMPIRE-1) to assess the role of ¹⁸ F-fluciclovine-PET/CT in improving cancer control relative to conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy for prostate cancer. Participants were patients suffering from prostate cancer with identifiable PSA post-prostatectomy and negative conventional imaging (no extrapelvic or bone findings). These were randomized (1:1) to radiotherapy directed by conventional imaging alone or to conventional imaging plus ¹⁸ F-fluciclovine-PET/CT. Findings revealed that significantly improved survival free from biochemical recurrence or persistence was achieved by including ¹⁸ F-fluciclovine-PET into postprostatectomy radiotherapy decision making and planning.